arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Savara, Inc.

SVRA Health Care Biotechnology: Pharmaceutical Preparations
$4.22
▼ -9.6% Today
as of Oct 23, 16:52 ET
Last 30 days -20.97% Sep 14 → Oct 23
$4.12 $4.48 $4.83 $5.19 $5.55 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$4.50
High
$4.58
Low
$4.13
Volume
$3M
Avg Vol
$2M
Mkt Cap
$1.0B
P/E (TTM)
—
Beta
—
52w High
$7.00
52w Low
$3.86
Div Yield
—
Shares Out
$205M

Recent Press Releases & News last 60 days · 5 items

Oct 21 · 17:10 PR Business Wire
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Oct 13 · 08:14 Simply Wall St.
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
Oct 12 · 20:05 PR Business Wire
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
▸ Show all 5 press releases & news Free account →

SVRA earnings at a glance

The options market is pricing a move of about ±3.1% after the report, a range of roughly $4.09 to $4.35 from today's $4.22. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.2% on average; after the most recent report on May 12, 2026 it moved -0.8%. That means options currently expect more movement than SVRA has typically delivered. SVRA beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 26%. The share price of $4.22 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.86
$7.00
11% of range
Avg surprise (last 4)
-7.9%
Avg reaction (last 2)
-1.2%
0% positive
Latest IV / EM
26%
EM ±3.1% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.66$-0.39$-0.11$0.16$0.43 Actual $-0.07Actual $-0.07Actual $-0.10Actual $-0.11Actual $-0.12Actual $-0.11Actual $-0.12Est $-0.12Actual $-0.14Est $-0.12Actual $-0.14Est $-0.13Actual $-0.15Est $-0.14Actual $-0.16 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-40M$-37M$-33M$-29M$-25M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.16 — — — — financials
Tue May 12, 2026Mar/2026 $-0.15 $-0.14 -7.1% -25.0% -0.8% earnings
Wed Nov 12, 2025Sep/2025 $-0.14 $-0.13 -7.7% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.14 $-0.12 -16.7% — — earnings
Tue May 13, 2025Mar/2025 $-0.12 $-0.12 0.0% — -1.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.11 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.12 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.11 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.10 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.07 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.07 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-41M$-39M—$-30M$-31M$-28M—$-26M
Net income$-40M$-37M—$-30M$-30M$-27M—$-24M
EPS (diluted)$-0.16$-0.15—$-0.14$-0.14$-0.12—$-0.11

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$42M$39M$33M$16M$17M$20M$15M$21M
Inventory————————
Total current assets$178M$209M$242M$128M$151M$177M$202M$226M
Total assets$192M$222M$253M$141M$164M$189M$213M$239M
Long-term debt$30M$30M$30M$30M$30M$30M$27M$27M
Total liabilities$48M$46M$50M$47M$43M$41M$41M$39M
Total equity$144M$176M$203M$94M$120M$148M$171M$199M

Implied volatility — last 90 days

21%172%322%472%623% Jun 17 — IV 623% · EM ±26.0%Jun 22 — IV 72% · EM ±14.9%Jun 30 — IV 429% · EM ±73.9%Jul 07 — IV 37% · EM ±4.8%Jul 08 — IV 50% · EM ±6.2%Jul 10 — IV 45% · EM ±5.0%Jul 13 — IV 125% · EM ±10.5%Jul 14 — IV 194% · EM ±14.1%Jul 20 — IV 118% · EM ±27.8%Jul 21 — IV 83% · EM ±19.3%Jul 22 — IV 62% · EM ±14.2%Jul 23 — IV 75% · EM ±17.0%Jul 24 — IV 37% · EM ±8.2%Jul 27 — IV 31% · EM ±6.4%Jul 28 — IV 37% · EM ±7.5%Jul 29 — IV 38% · EM ±7.6%Jul 31 — IV 43% · EM ±8.2%Aug 03 — IV 48% · EM ±8.4%Aug 04 — IV 48% · EM ±8.3%Aug 07 — IV 77% · EM ±12.0%Aug 10 — IV 50% · EM ±7.0%Aug 24 — IV 29% · EM ±6.1%Aug 25 — IV 214% · EM ±43.8%Aug 26 — IV 27% · EM ±5.3%Aug 27 — IV 130% · EM ±25.5%Sep 02 — IV 22% · EM ±3.7%Sep 21 — IV 141% · EM ±29.4%Sep 22 — IV 111% · EM ±22.6%Sep 23 — IV 62% · EM ±12.5%Sep 24 — IV 81% · EM ±15.8%Sep 25 — IV 63% · EM ±12.0%Sep 28 — IV 72% · EM ±12.8%Sep 29 — IV 51% · EM ±8.9%Oct 06 — IV 114% · EM ±15.1%Oct 07 — IV 40% · EM ±5.0%Oct 08 — IV 26% · EM ±3.1%

Sector peers

OPK
Opko Health, Inc.
$1.0B $1.63+1.9%
PCRX
Pacira BioSciences, Inc.
$1.0B $36.42+0.2%
JANX
Janux Therapeutics, Inc.
$1.1B $16.66-1.6%
MNKD
MannKind Corporation
$1.1B $3.19+4.6%
KURA
Kura Oncology, Inc.
$949M $9.61-2.7%
MLTX
MoonLake Immunotherapeutics
$917M $11.85+11.3%

SVRA earnings FAQ

What is SVRA's expected move for earnings?

Options currently price a move of about ±3.1%, or $0.13 per share either way from $4.22.

How does SVRA stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.2%, up 0 times and down 2 times.

What is SVRA's implied volatility?

SVRA's at-the-money implied volatility is about 26% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in